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Abstract 
Neprilysin is a transmembrane M13 zinc metalloprotease responsible for the degradation 
of several biologically active peptides including insulin, enkephalin, substance P, bradykinin, 
endothelin-1, neurotensin and amyloid-β. The protein has received attention for its role in 
modulating blood pressure responses with its inhibition producing an antihypertensive 
response. To date, several inhibitor bound crystal structures of the human neprilysin 
extracellular domain have been determined, but, a structure free of bound inhibitor or 
substrate has yet to be reported. Here, we report the first crystal structure free of substrate 
or inhibitor for the extracellular catalytic domain of human neprilysin at 1.9 Å resolution. 
This structure will provide a reference point for comparisons to future inhibitor or substrate 
bound structures. The neprilysin structure also reveals that a closed protein conformation 
can be adopted in protein crystals absent of bound substrate or inhibitor. 
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1. Introduction 
Neprilysin (NEP, EC 3.4.24.11), also known as neutral endopeptidase, neuropeptidase, 
CD10 and enkephalin, is a transmembrane protease that belongs to the M13 family of zinc 
metalloproteases. NEP can digest a broad range of peptide substrates including insulin, 
enkephalin, substance P, bradykinin, endothelin-1, neurotensin and amyloid-β (Kerr et al., 
1974; Skidgel et al., 1984; Howell et al., 1995). In addition to the broad substrate specificity, 
NEP can cleave each substrate at a number of locations but exhibits a preference for the 
amino side of hydrophobic residues (Hersh et al., 1986). 
NEP is located at the plasma membrane and consist of three domains. The short 
intracellular and transmembrane domains are 27 and 23 residues in length and the third 
larger extracellular catalytic domain which is 699 residues in length. The extracellular 
domain contains a large central cavity where the conserved zinc binding motif HEXXH is 
located. The two histidine residues are responsible for the coordination of the zinc ion, 
while the glutamate is directly involved in catalysis. This conserved region has been 
targeted for inhibition to produce an antihypertensive response. To date eight inhibitor 
bound structures of the human NEP extracellular domain are available in the Protein Data 
Bank (Oefner et al., 2000; Oefner et al., 2004; Sahli et al., 2005; Oefner et al., 2007; 
Glossop et al., 2011; Schiering et al., 2016) but a structure free of bound inhibitor or 
substrate has yet to be reported. Here, we report the first crystal structure of the substrate-
free extracellular domain of human NEP. 
2. Materials and methods 
2.1 Expression and purification 
All reagents for expression and purification were sourced from Sigma-Aldrich or Fisher 
Scientific unless otherwise specified.  
A clone of Pichia pastoris GS115 expressing the extracellular catalytic domain of 
human NEP was purchased from Invitrogen. The clone contained human NEP (Tyr51-
Trp749) integrated into the P. pastoris genome. The cytoplasmic (Gly1-Glu27) and 
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transmembrane (Ile28-Ala50) domains of NEP were absent in the construct to increase the 
probability of protein crystallisation. The protein of interest was expressed with an N-
terminal 6x histidine tag and a secretion peptide sequence. 
Expression of the P. pastoris clone was completed in accordance with the Invitrogen 
manual for recombinant protein expression. A glycerol stock of the P. pastoris clone was 
used to inoculate a starter culture containing 25ml of BMGY (1% Yeast extract, 2% Peptone, 
22.968 g L-1 K2HPO4, 118.048 g L-1 KH2PO4 pH 6.0, 1.34% Yeast nitrogen base, 4x10-5% 
Biotin and 1% Glycerol) in a 250 mL baffled flask. The starter culture was incubated 
overnight at 30oC. 10 mL of the overnight culture was used to inoculate an expression 
culture in 2 L baffled flasks containing 250 mL BMGY. The expression culture was 
incubated at 30oC for 24 hours. 
After 24 hours the expression culture was harvested at 6000 RCF for 20 minutes at 
19oC. The supernatant was discarded, and the cell pellet was re-suspended in 250 mL of 
BMMY (1% Yeast extract, 2% Peptone, 22.968 g L-1 K2HPO4, 118.048 g L-1 KH2PO4 pH 
6.0, 1.34% Yeast nitrogen base, 4x10-5% Biotin and 0.5% Methanol) for induction. Re-
suspended cells were transferred to a new 2 L baffled flask. The culture was incubated for 
72 hours at 30oC. 5 mL of 50% methanol was added to the culture 24 and 48 hours. 
After 72 hours of induction the culture was harvested at 6000 RCF for 20 minutes at 
19oC. The supernatant was collected and the cell pellet was discarded. Tris and NaCl were 
added to the supernatant to give final concentrations of 25 mM Tris and 150 mM NaCl. 
Following the addition of Tris and NaCl the supernatant showed some precipitation which 
was removed through a 0.22 μm filter (Millipore). 
The P. pastoris culture supernatant was loaded onto a 5 mL HisTrap affinity column 
(GE Healthcare Life Sciences) at 2 mL min-1 pre-equilibrated with Buffer A (25 mM Tris, 
150 mM NaCl, 2 mM MgCl2 pH 7.5). Following loading, the column was washed with 2% 
Buffer B (25 mM Tris, 150 mM NaCl, 2 mM MgCl2 and 500 mM Imidazole pH 7.5) until the 
UV trace returned to baseline. Bound NEP was eluted using a gradient of Buffer B between 
2-100%. 2 mL fractions were collected and analysed using SDS-PAGE with a 10% 
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acrylamide gel to confirm the presence of protein. 
Fractions containing protein were concentrated to a volume under 5 mL in a centrifuge 
at 4000 RCF. For concentration a centrifuge filter unit with a 30 kDa molecule weight cut 
off (Millipore) was used. The concentrated protein containing sample was then loaded at 5 
mL min-1 onto a HiPrep 26/10 Desalting column (GE Healthcare Life Sciences) pre-
equilibrated with Buffer A. Eluted protein containing fractions were kept at 4oC for short 
term storage or -20oC for longer term storage. 
2.2 Enzymatic assay 
The enzymatic activity of NEP was assayed by measuring cleavage of the fluorogenic 
peptide Mca-RPPGFSAFK-(Dnp) (Enzo Life Sciences). A stock solution of 1 mM Mca-
RPPGFSAFK(Dnp) dissolved in 100% DMSO was stored at -20oC. Dilutions of this stock 
where made using purification Buffer A. Enzymatic assays were conducted using 50 μL of 
20 μM Mca-RPPGFSAFK-(Dnp) and 50 μL of 8 nM purified NEP. 50 μL of 8 nM bovine 
serum albumin (BSA) was used as a negative control. Solutions were manually added to 
a black 96 well microplate (Greiner Bio-One). 
Fluorescence activity assays were performed using a CLARIOstar high-performance 
microplate reader (BMG LABTECK). Excitation was achieved at 328 nm and emission was 
detected at 393 nm. Readings were taken in triplicate at 15 second intervals for a length 
of 45 minutes.  
2.3 Crystallisation 
Protein crystallisation was performed with NEP (8 mg/mL) mixed 1:1 with crystallisation 
buffer 0.2 M KNO3 and 20% (w/v) PEG3350 (Molecular Dimensions, England). The mixed 
solution was manually dispensed into 24-well plates (Molecular Dimensions, England) for 
crystallisation experiments using hanging drop vapour diffusion. Plates were stored at 18oC 
and crystals formed within a month. Crystals used for data collection were mounted in a 
loop and flash-cooled for storage in liquid nitrogen without cryoprotectant. 
2.4 Data collection, structure determination and refinement 
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X-ray diffraction data were collected at the i03 beamline in Diamond Light Source (Didcot, 
Oxford) at a wavelength of 0.976 Å (12.7 keV) with an oscillation range of 0.1o using a 
Pilatus3 6M detector.  
Raw X-ray diffraction data were indexed and integrated using DIALS (Waterman et al., 
2016). Data were then scaled and merged using AIMLESS within the CCP4 suite (Evans 
et al., 2013; Winn et al., 2011). A resolution cut off of 1.9 Å was applied based on statistics 
generated from AIMLESS (Evans et al., 2013). 
PHASER (McCoy et al., 2007) was used to perform molecular replacement using 
structure 5JMY (Schiering et al., 2016) on the merged and scaled data from AIMLESS. A 
single structural solution was provided with a TFZ score of 14.18. After PHASER the 
structure was refined using REFMAC5 (Murshudov et al., 2011). PHENIX was used 
towards the end of refinement for its superior handling of protein glycosylation (Adams et 
al., 2010). Visualisation and model building were performed using COOT (Emsley et al., 
2010). 
Programs MolProbity (Chen et al., 2010) and PDB validation (Berman et al., 2003) 
were used to assess any steric and geometry outliers within the modelled structure. The 
coordination of the active site zinc ion was assessed using the CheckMyMetal server 
(Zheng et al., 2017) and a composite omit map was generated using Phenix (Terwilliger et 
al., 2008) to provide a bias free map of the active site. Images were created using either 
PyMOL (Schrödinger, LLC, 2015) or CCP4mg (McNicholas et al., 2011) and APBS was 
used for determination of protein cavity electrostatic potential (Baker et al., 2001). RMSD 
values for main chain superpositions were calculated using LSQ in COOT (Emsley et al., 
2010) and cavity volumes were calculated using CASTp (Binkowski et al., 2003).  
The final refined structure had Rwork and Rfree of 18.99% and 23.54% respectively and 
was deposited with the Protein Data Bank under code 6GID (Table 1). 
 
3. Results and discussion 
Here we report the first substrate-free crystal structure for the extracellular catalytic domain 
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of human NEP (Gly54-Trp749). The structure was determined in the trigonal space group 
P3221 with a single molecule in the asymmetric unit to a resolution of 1.9 Å. The protein 
used for this structural study was expressed and purified in P. pastoris and has been shown 
to be catalytically active (Figure 1).  
The reported structure was refined to give final Rwork and Rfree values of 18.99% and 
23.54% respectively. Overall, 98% of residues are within the preferred region of the 
Ramachandran plot with 2% allowed and no outliers. The details of data collection and 
refinement statistics are presented in Table 1.  
3.1 General features 
The NEP extracellular domain is ellipsoid in shape with a long and short axis of 86 Å and 
60 Å respectively. The secondary structure of NEP is mainly alpha helical in nature and 
can be further separated into two large lobe-like subdomains connected by a smaller linker 
region. The linker region is formed of four alpha helical segments distributed non-
consecutively in the protein sequence (Figure 2). Subdomain 1 consists of N-terminal 
residues while subdomain 2 consists of C-terminal residues. Together, subdomains 1 and 
2 enclose a large central cavity. 
Four sites of N-linked glycosylation have been confirmed at positions N144, N284 and 
N324 in subdomain 2 and position N627 in subdomain 1. Electron density allowed a single 
N-acetylglucosamine residue to be modelled at each of these sites. 
The catalytic site of NEP, located within the cavity surface of subdomain 1, is based 
around a zinc ion and conserved active site motif HEXXH. The zinc ion is coordinated by 
conserved residues H583 (2.02 Å) and H587 (2.10 Å) and additional coordination is 
provided by E646 (1.93 Å). The third conserved residue, E584, is involved in the catalytic 
mechanism and adopts a position above the zinc ion completing coordination sphere. 
The coordinated zinc ion and surrounding residues creates a small binding pocket with 
subsites S1, S1' and S2' (Figure 3). Inhibitors designed for NEP have revealed 
characteristics about the subsites. The S1 site has low impact on the overall affinity for 
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binding and displays relaxed specificity (Oefner et al., 2000). S1' subsite forms a 
hydrophobic pocket that exhibits specificity for large hydrophobic and aromatic side chains 
(Tiraboschi et al., 1999). This accounts for the preference for NEP to cleavage sites at the 
amino side of hydrophobic residues. The S2' subsite displays relaxed specificity and can 
accommodate bulky side chains (Dion et al., 1997). 
3.2 Modelling active site density 
In addition to residues H583, H587 and E646, a ligand is required to create an acceptable 
coordination sphere for the catalytic zinc ion. In the structure reported here, this is provided 
by a phosphate ion (2.07 Å and 2.36 Å) carried through from the P. pastoris expression 
growth media. The final refined structure shows the modelled phosphate ion has a good fit 
to the electron density (Figure 4A). A composite omit map was used to generate bias-free 
electron density for the region surrounding the catalytic zinc ion (Figure 4B). The omit map 
supported the placement of the phosphate ion, with good density present above the zinc 
ion. The full coordination sphere was evaluated using the CheckMyMetal web server 
(Zheng et al., 2017) to confirm the acceptable coordination interactions were modelled. 
The presence of a ligand coordinating the catalytic zinc ion has been reported in other 
native zinc metalloprotease crystal structures that share the HEXXH motif. In angiotensin-
converting enzyme (ACE, 1O8A) an acetate is responsible for coordinating the zinc atom 
(Natesh et al., 2003). Other structures including insulin-degrading enzyme (IDE, 2JG4) (Im 
et al., 2007) and thermolysin (1TLX and 2TLX) (English et al., 1999), have water molecules 
coordinating the zinc ion. However, in these structures the water molecule does not 
completely account for the electron density above the zinc ion and the coordination 
distances between water molecule and the zinc ion are greater than acceptable lengths 
(Zheng et al., 2017).  
It is clear that the molecule responsible for the coordination of the catalytic zinc ion 
has an area of density that is difficult to model with certainty in native zinc metalloprotease 
structures. It is likely that a range of ligands or water molecules are responsible for 
coordinating the zinc ion across the different protein molecules present within the protein 
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crystal. As a result, the density describes an average of these ligands and water molecules. 
In the structure reported here, a phosphate ion has been modelled to coordinate the zinc 
ion based on the evidence present above. 
The structure reported here contains additional weaker density in the S1' and S2' 
subsites. That weaker density has been modelled as a polyethylene glycol fragment (PEG) 
acquired from the crystallisation buffer. Occupancy of the PEG fragment was refined using 
Phenix to 0.95. The fragment has several favourable contacts to the phosphate ion but has 
limited interactions to active site residues with no contacts closer than 3.15 Å in length. 
The native ACE, IDE and thermolysin structures also exhibit additional weak density 
in the active site. It is likely that a range of small molecules present in the crystallisation 
buffers show affinity for the binding site accounting for weak density in the region. Due to 
the presence of a PEG molecule and phosphate ion we describe this structure as 
substrate-free opposed to native. 
3.3 Active site flexibility 
To date, eight inhibitor bound crystal structures of NEP extracellular domain are currently 
available in the Protein Data Bank. These structures were superimposed onto the 
substrate-free NEP structure and active site residues were visually inspected for 
conformational changes. Two inhibitor bound structures were selected to accurately 
describe all conformational changes that were present across the eight available structures. 
These two structures are compared to substrate-free NEP below. 
First, the substrate-free crystal structure is compared to crystal structure 5JMY 
(Schiering et al., 2016) which contains inhibitor LBQ657. Conformational changes in 
residues F106 and W693 can be seen between our substrate-free structure and 5JMY 
(Figure 5A). W693 displays a large shift that increases the volume of the S1' pocket and 
allows the biphenyl group of LBQ657 to occupy the site. The shift in W693 causes rotation 
in F106 altering the S2' subsite. The second comparison is to crystal structure 1DMT 
(Oefner et al., 2000) which contains inhibitor phosphoramidon. Conformational changes in 
R110 form the interface of the S2’ subsite and accommodate for the bulky side chain of 
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phosphoramidon (Figure 5B). 
The flexibility in residues listed above helps explain how NEP can accommodate a 
number of different peptide substrates at different locations with variability in the specific 
amino acid that interacts with the cleavage site. W693, F106 and R110 are the only active 
site amino acids that show significant motions when compared to the eight published 
inhibitor bound crystal structures. 
3.4 Conformational flexibility 
The crystal structure reported here for the NEP extracellular domain is in a closed 
conformation. Two small solvent accessible entrances to the large cavity are located at the 
front and rear of the protein measuring approximately 8 Å and 6 Å at their narrowest points 
(Figure 7A). These entrances are too small for the entry of substrate or inhibitor indicating 
NEP must undergo conformational changes to adopt an open conformation.  
Published inhibitor bound structures all report NEP in closed conformations. 
Superpositions of these structures with substrate-free NEP (Figure 6), and RMSD values 
calculated for the superpositions (Table 2), indicate the close conformational similarity. This 
reveals binding of substrate or inhibitor is not required to stabilise the closed conformation 
in the NEP crystal structure. It is unclear if the protein only opens when interacting with 
substrate or whether the closed conformation is a result of the protein existing in a crystal 
structure. 
In a closed conformation NEP’s large central cavity has an approximate volume of 
5000 Å3 which is a smaller volume than many of the peptides it is responsible for cleaving 
(Malito et al., 2008). Previous studies have revealed amyloid-β, a substrate of NEP, is 
cleaved at a number of locations within the centre of the polypeptide chain (Sexton et al., 
2012; Webster et al., 2014). Cleavage in this manner is a characteristic feature seen in 
other zinc metalloproteases including insulin degrading enzyme (IDE) which has a similar 
the two lobe-like domain structure with large central cavities. 
In order for substrate cleavage to occur, it is likely that large movements in the 
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subdomains are required for substrate access into the active site. Structures of IDE have 
revealed that a separation of the two lobe-like domains allows entry of substrate before a 
closed conformation is adopted completely engulfing the substrate into the central cavity 
(McCord et al., 2013). Given the smaller size of the NEP cavity it is unlikely that the protein 
completely engulfs its substrate, but it is clear that motion is required for access to the 
active site. The exact mechanism will remain elusive until peptide bound structures of NEP 
are determined. 
The electrostatic surface charge of the cavity has been analysed using APBS (Figure 
7B). A striking electrostatic difference between the top and bottom surfaces of the cavity is 
present. The top surface, contributed by subdomain 2, displays a large area of positive 
electrostatic potential. The opposite is observed for the bottom surface, contributed by 
subdomain 1, where a large negative electrostatic potential is present in and in proximity 
to the catalytic site. It is also observed that the front entrance to the cavity possesses a 
strong negative electrostatic potential, while the rear entrance possesses a strong positive 
electrostatic potential. These electrostatic features may be critical for guidance of substrate 
to the active site and important for substrate binding. 
 
4. Conclusion 
In this report we have presented a substrate-free crystal structure for the extracellular 
domain of human NEP. The active site of this structure has been compared to other 
available inhibitor bound structures revealing flexibility in active site residues W693, F106 
and R110. Flexibility in these residues is critical for allowing the active site to accommodate 
a variety of substrates binding at a range of positions. Additionally, we also note the central 
cavity of NEP has striking electrostatic potential differences between the top and bottom 
side. The function of these differences is unknown but are likely involved in substrate 
interaction. 
The crystal structure of substrate-free NEP reveals that a closed protein conformation 
can be retained in the absence of bound substrate or inhibitor. The mechanism for 
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substrate entrance into the active site remains unclear, but clues provided by IDE suggest 
large domain shifts may be required for substrate entry. The structure reported here 
provides a key reference point for any future structural studies investigating substrate 
binding and conformational movement.  
 
Acknowledgements 
We thank Diamond Light Source for access to beamline I03 (proposal mx17212) that 
resulted in the data presented here. S.M is supported by a post-graduate studentship from 
the Alzheimer’s Society (UK) awarded to K.R.A. and V.S. [grant number - 286 (AS-
PhD2015b-006)]. This research made use of the Balena High Performance Computing 
(HPC) Service at the University of Bath. 
 
Author contributions 
S.M performed all the experiments, analysed the data and wrote the manuscript. V.S. 
supervised the study and edited the manuscript. K.R.A. conceptualised and supervised the 
study, analysed the data and edited the manuscript. 
 
Additional information 
Accession code: The atomic coordinates and structure factors (code 6GID) have been 
deposited in the Protein Data Bank (http://www.pdb.org). 
 
Competing financial interests 
The authors declare no competing financial interests. 
 
References 
Adams, P.D., Afonine, P. V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., 
Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., McCoy, A.J., Moriarty, N.W., 
 13 
 
Oeffner, R., Read, R.J., Richardson, D.C., Richardson, J.S., Terwilliger, T.C., Zwart, 
P.H., 2010. Phenix: a comprehensive Python-based system for macromolecular 
structure solution. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 213–221.  
Baker, N.A., Sept, D., Joseph, S., Holst, M.J., McCammon, J.A., 2001. Electrostatics of 
nanosystems: Application to microtubules and the ribosome. Proc. Natl. Acad. Sci. 
98, 10037–10041.  
Berman, H., Henrick, K., Nakamura, H., 2003. Announcing the worldwide Protein Data 
Bank. Nat. Struct. Mol. Biol. 10, 980.  
Binkowski, T., Naghibzadeh, S., Liang, J., 2003. CASTp: Computed atlas of surface 
topography of proteins. Nucleic Acids Res. 31, 3352-3355. 
Chen, V.B., Arendall, W.B., Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., 
Murray, L.W., Richardson, J.S., Richardson, D.C., 2010. MolProbity: all-atom 
structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D Biol. 
Crystallogr. 66, 12–21.  
Dion, N., Cohen, P., Crine, P., Boileau, G., 1997. Characterisation of neprilysin (EC 
3.4.24.11) S2′ subsite. FEBS Lett. 411, 140–144.  
Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., 2010. Features and development of 
Coot. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 486–501.  
English, A.C., Done, SH., Caves, S.L., Groom, R.C., Hubbard, E.R,. 1999. Locating 
interaction sites on proteins: the crystal structure of thermolysin soaked in 2% to 100% 
isopropanol. Proteins 37, 628–640. 
Evans, P.R., Murshudov, G.N., 2013. How good are my data and what is the resolution? 
Acta Crystallogr. Sect. D Biol. Crystallogr. 69, 1204–1214.  
Glossop, M.S., Bazin, R.J., Dack, K.N., Fox, D.N.A., MacDonald, G.A., Mills, M., Owen, 
 14 
 
D.R., Phillips, C., Reeves, K.A., Ringer, T.J., Strang, R.S., Watson, C.A.L., 2011. 
Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral 
endopeptidase inhibitors. Bioorg. Med. Chem. Lett. 21, 3404–3406.  
Hersh, L.B., Morihara, K., 1986. Comparison of the subsite specificity of the mammalian 
neutral endopeptidase 24.11 (Enkephalinase) to the bacterial neutral endopeptidase 
Thermolysin. J. Biol. Chem. 261, 6433–6437. 
Howell, S., Nalbantoglu, J., Crine, P., 1995. Neutral endopeptidase can hydrolyze β-
amyloid (1-40) but shows no effect on β-amyloid precursor protein metabolism. 
Peptides 16, 647–652. 
Im, H., Manolopoulou, M., Malito, E., Shen, Y., Zhao, J., Neant-Fery, M., Sun, C.Y., 
Meredith, S.C., Sisodia, S.S., Leissring, M.A., 2007. Structure of substrate-free 
human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced 
conformational switch of IDE. J. Biol. Chem. 282, 25453–25463. 
Kerr, M.A., Kenny, A.J., 1974. The purification and specificity of a neutral endopeptidase 
from rabbit kidney brush border. Biochem. J. 137, 477–488. 
Malito, E., Hulse, R.E., Tang, W.J., 2008. Amyloid-β degrading cryptidases: insulin 
degrading enzyme, presequence peptidase, and neprilysin. Cell. Mol. Life Sci. 65, 
2574–2585.  
McCord, L.A., Liang, W.G., Dowdell, E., Kalas, V., Hoey, R.J., Koide, A., Koide, S., Tang, 
W.-J., 2013. Conformational states and recognition of amyloidogenic peptides of 
human insulin-degrading enzyme. Proc. Natl. Acad. Sci. 110, 13827–13832.  
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., 
2007. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674.  
McNicholas, S., Potterton, E., Wilson, K.S., Noble, M.E.M., Emsley, P., Murshudov, G.N., 
Cohen, S., Perrakis, A., Noble, M., 2011. Presenting your structures: the CCP4mg 
 15 
 
molecular-graphics software. Acta Crystallogr. Sect. D Biol. Crystallogr. 67, 386–394.  
Murshudov, G.N., Skubák, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., 
Winn, M.D., Long, F., Vagin, A.A., 2011. REFMAC5 for the refinement of 
macromolecular crystal structures. Acta Crystallogr. Sect. D Biol. Crystallogr. 67, 
355–367.  
Natesh R Schwager S.L., Sturrock, E.D., Acharya, K.R., 2003. Crystal structure of the 
human angiotensin-converting enzyme-lisinopril complex. Nature 421, 551–554. 
Oefner, C., D’Arcy, A., Hennig, M., Winkler, F.K., Dale, G.E., 2000. Structure of human 
neutral endopeptidase (neprilysin) complexed with phosphoramidon. J. Mol. Biol. 296, 
341–349.  
Oefner, C., Pierau, S., Schulz, H., Dale, G.E., 2007. Structural studies of a bifunctional 
inhibitor of neprilysin and DPP-IV. Acta Crystallogr. Sect. D 63, 975–981.  
Oefner, C., Roques, B.P., Fournie-Zaluski, M.C., Dale, G.E., 2004. Structural analysis of 
neprilysin with various specific and potent inhibitors. Acta Crystallogr. Sect. D 60, 
392–396.  
Sahli, S., Frank, B., Schweizer, W.B., Diederich, F., Blum‐ Kaelin, D., Aebi, J.D., Böhm, H., 
Oefner, C., Dale, G.E., 2005. Second‐ Generation Inhibitors for the Metalloprotease 
Neprilysin Based on Bicyclic Heteroaromatic Scaffolds: Synthesis, Biological Activity, 
and X‐ Ray Crystal‐ Structure Analysis. Helv. Chim. Acta 88, 731–750.  
Schiering, N., D ’Arcy, A., Villard, F., Ramage, P., Logel, C., Cumin, F., Ksander, G.M., 
Wiesmann, C., Karki, R.G., Mogi, M., 2016. Structure of neprilysin in complex with 
the active metabolite of sacubitril Sci. Rep. 6, 27909. doi: 10.1038/srep27909. 
Schrödinger, L., 2015. The PyMOL Molecular Graphics System, Version 1.8. 
Sexton, T., Hitchcook, L.J., Rodgers, D.W., Bradley, L.H., Hersh, L.B., 2012. Active Site 
 16 
 
Mutations Change the Cleavage Specificity of Neprilysin. PLoS One 7, 1–10.  
Skidgel, R.A., Engelbrecht, S., Johnson, A.R., Erdös, E.G., 1984. Hydrolysis of substance 
P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5, 
769–776.  
Terwilliger, T.C., Grosse-Kunstleve, R.W., Afonine, P.V, Moriarty, N.W., Adams, P.D., Read, 
R.J., Zwart, P.H., Hung, L.W., 2008. Iterative-build OMIT maps: map improvement by 
iterative model building and refinement without model bias. Acta Crystallogr. Sect. D 
64, 515-524 
Tiraboschi, G., Jullian, N., Thery, V., Antonczak, S., Fournie-Zaluski, M.-C., Roques, B.P., 
1999. A three-dimensional construction of the active site (region 507–749) of human 
neutral endopeptidase (EC.3.4.24.11). Protein Eng. Des. Sel. 12, 141–149.  
Waterman, D.G., Winter, G., Gildea, R.J., Parkhurst, J.M., Brewster, A.S., Sauter, N.K., 
Evans, G., Sauter, K., Winter, G., Toyokawa, H., Wagner, A., 2016. Diffraction-
geometry refinement in the DIALS framework. Acta Crystallogr. Sect. D Biol. 
Crystallogr. 39, 558–575.  
Webster, C.I., Burrell, M., Olsson, L.-L., Fowler, S.B., Digby, S., Sandercock, A., Snijder, 
A., Tebbe, J., Haupts, U., Grudzinska, J., Jermutus, L., Andersson, C., 2014. 
Engineering neprilysin activity and specificity to create a novel therapeutic for 
Alzheimer’s Disease. PLoS One 9, e104001.  
Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, 
R.M., Krissinel, E.B., Leslie, A.G.W., McCoy, A., McNicholas, S.J., Murshudov, G.N., 
Pannu, N.S., Potterton, E.A., Powell, H.R., Read, R.J., Vagin, A., Wilson, K.S., IUCr, 
2011. Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. 
D Biol. Crystallogr. 67, 235–242. 
Zheng, H., Cooper, D.R., Porebski, P.J., Shabalin, I.G., Handing, K.B., Minor, W., 2017. 
 17 
 
CheckMyMetal: a macromolecular metal-binding validation tool. Acta Crystallogr. 
Sect. D 73, 223–233.  
  
 18 
 
 
Table 1. Neprilysin X-ray data collection and refinement statistics. 
Beamline I03, DLS 
Wavelength (Å) 0.976 
  
Crystallographic statistics  
Space group P3221 
Unit cell dimensions  
a,b,c (Å) 107.42, 107.42, 112.32 
α, β, γ ( ◦ ) 90.00, 90.00, 120.00 
Resolution range (Å) 93.03-1.90 (1.94-1.90) 
Rmerge 0.128 (1.384) 
Rmeas 0.130 (1.410) 
CC1/2 1.000 (0.665) 
⟨ I/σ ( I )⟩  25.3 (3.7) 
Completeness (%) 100 (100) 
No. observed reflections 3193442 (201035) 
No. unique reflections 59422 (3790) 
Multiplicity 53.7 (53.0) 
  
Refinement  
Rwork /Rfree (%) 18.99/23.54 
R.m.s deviations  
Bond lengths (Å) 0.009 
Bond angles ( ◦ ) 0.894 
Ramachandran statistics  
Favoured (%) 98 
Allowed (%) 2 
Outliers (%) 0 
Wilson B-factor (Å2 ) 30.8 
Average B-factors (Å2 )  
Protein 34.0 
Water 38.1 
 
Zinc 24.9 
Phosphate 37.1 
Carbohydrate 54.5 
No. of atoms  
Protein 5599 
Water 463 
Carbohydrate 56 
PDB code 6GID 
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Values in parentheses are for highest-resolution shell. 
 
 
Table 2. RMSD values from published inhibitor bound NEP structures superimposed onto 
the substrate-free structure. RMSD values were calculated in COOT using a least squares 
comparison for mainchain residues 54 – 749.   
PDB code RMSD Reference 
5JMY 0.426 Schiering et al., 2016 
2YB9 0.354 Glossop et al., 2011 
2QPJ 0.452 Oefner et al., 2007 
1Y8J 0.421 Sahli et al., 2005 
1R1H 0.385 Oefner et al., 2004 
1R1I 0.484 Oefner et al., 2004 
1R1J 0.421 Oefner et al., 2004 
1DMT 0.340 Oefner et al., 2000 
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Figure legends 
Figure 1. (A) SDS-PAGE of purified NEP sample. (B) Enzymatic assay for NEP measuring 
relative fluorescent units (RFU) over time. Fluorescent substrate Mca-RPPGFSAFK(Dnp) 
(10 μM), NEP (8 nM) and BSA (8 nM) were used. Each assay was conducted in triplicate 
and the average has been plotted with standard error bars. 
Figure 2. Three-dimensional ribbon diagram of the NEP extracellular domain. The 
extracellular domain is further split into two subdomains coloured green for subdomain 1, 
red for subdomain 2 and cyan for the linker region. Observed glycan residues are displayed 
in purple and the zinc ion is displayed in grey. 
Figure 3. NEP active site binding pocket labelled with subsites and residues 
Figure 4. The active site zinc ion is coordinated by residues H583, H587, E646 and a 
phosphate ion. An additional PEG fragment is located in proximity to the phosphate ion. 
Electron density maps of the coordination sphere of the refined structure is shown. (A) 
2mFo-DFc and (B) composite omit map. Both maps are shown to a contour level of 1.5ơ. 
Figure 5. Substrate-free NEP active site (green) is superimposed with 5JMY (Schiering et 
al., 2016) (pink) (B) and 1DMT (Oefner et al., 2000) (brick) (C). Inhibitors LBQ657 and 
phosphoramidon are shown in cyan and jade, with the zinc ion shown in grey. 
Figure 6. Mainchain superpositions of substrate-free NEP with published structures: 5JMY 
(magenta), 2YB9 (light grey), 2QPJ (violet), 1Y8J (lime green), 1R1H (purple), 1R1I (grey), 
1R1J (blue) and 1DMT (cyan). 
Figure 7. (A) Molecular surface representation of front (left) and rear (right) of NEP and 
coloured green for subdomain 1, red for subdomain 2 and cyan for linker region. Small 
solvent entrances are indicated with an asterisk. (B) Molecular surface representation of 
front (left) and rear (right) for the central cavity of NEP. Electrostatic charge has been 
calculated with APBS. The electrostatic potential is measured in eV with scale bar indicated 
within the figure. 
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